Aruvant’s Data Presented in Oral Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting Demonstrates Promise of ARU-1801 as a Potentially Curative Treatment for Sickle Cell Disease

–Data from improved manufacturing process resulted in significantly improved ARU-1801 product profile– New York, NY, Dec. 7, 2020 – Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, announced new data demonstrating the...